Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JK1201I in small cell lung cancer
CTR20212623Phase 2Completed
- Sponsor
- Tianjin Keyken Technology
- Start
- Oct 2021
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of pegirinotecan in small cell lung cancer (SCLC), sponsored by Tianjin Keyken Technology. Started Oct 2021; status: completed.
02
Drugs
pegirinotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20212623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212623.